Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine A microemulsion: Results of a 12-month, randomized, multicenter study

Transplantation

Volumn 79, Issue 5, 2005, Pages 577-583

  Stefoni, Sergio ^a   Midtved, Karsten ^b   Cole, Edward ^c   Thervet, Eric ^d   Cockfield, Sandra ^e   Buchler, Matthias ^f   Toselli, Lorenzo ^g   Pallardo, Luis M ^h   Schena, Francesco P ⁱ   Pilmore, Helen ^j   Kessler, Michèle ^k   Chadban, Steve ^l   Carreño, César Agost ^m  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g CRAI Norte   (Argentina)

^h HOSPITAL UNIVERSITARIO DR PESET   (Spain)

ⁱ UNIVERSITY OF BARI   (Italy)

^j AUCKLAND CITY HOSPITAL   (New Zealand)

^k CHU NANCY BRABOIS   (France)

^l ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^m Sanatorio Mitre   (Argentina)

more..

Author keywords

C2 monitoring; Cyclosporine A; Kidney transplantation; MO2ART; Neoral

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACUTE GRAFT REJECTION; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HIRSUTISM; HUMAN; KAPLAN MEIER METHOD; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MONITORING; MULTICENTER STUDY; OUTCOMES RESEARCH; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT;

ADULT; AGED; BIOPSY; CYCLOSPORINE; DRUG MONITORING; EMULSIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 20144375595     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000153158.91683.34     Document Type: Article

References (17)

1. 2). Transplantation 2002; 73: 953-959.
2. 2 monitoring in stable renal transplant recipients may reduce cyclosporine nephrotoxicity. Transplantation 2003; 75: 2086-2090.
3. 2 cyclosporine using Neoral immunosuppression. Am J Transplant 2003; 3(suppl 5): 324 (Abstract 673).
4. Cantarovich M, Barkun JS, Tchervenkov JI, et al. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr post-dose levels in stable liver transplant patients. Transplantation 1998; 66: 1621-1627.
5. Cantarovich M, Besner JG, Barkun JS, et al. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998; 12: 243-249.
6. Glanville AR, Hopkins PM, Aboyouri CL, et al. Clinical utility of cyclosporin C2 monitoring after lung transplantation (LTX). J Heart Lung Transplant 2002; 21: 143 (Abstract 246).
7. 2 monitoring as the predictor in the de novo renal transplant recipients - a prospective one-year study. XIXth International Congress of the Transplant Society, 25-30 August 2002, Miami, Florida. Abstract 23.
8. 2 monitoring on cyclosporin microemulsion. Transplantation 2003; 76: 903-908.
9. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
10. Nankivell BJ, Gruenewald SM, Allen R, et al. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683-1689.
11. Opelz G, Döhler B. Cyclosporine and long-term kidney graft survival. Transplantation 2001; 72: 1267-1273.
12. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55-62.
13. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral®) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148-156.
14. 2 level for chronic renal allograft dysfunction. Clin Transplant 2003; 35: 2894-2898.
15. 2 monitoring in long-term renal transplant patients receiving cyclosporine microemulsion. Transplantation 2005 (in press).
16. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-318.
17. Opelz G, Wujciak W, Ritz E for the Collaborative Transplant Study. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53: 217-222.